0001415889-24-004234.txt : 20240216 0001415889-24-004234.hdr.sgml : 20240216 20240216182513 ACCESSION NUMBER: 0001415889-24-004234 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240215 FILED AS OF DATE: 20240216 DATE AS OF CHANGE: 20240216 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Colgan Erin CENTRAL INDEX KEY: 0001843563 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39980 FILM NUMBER: 24649991 MAIL ADDRESS: STREET 1: C/O SENSEI BIOTHERAPEUTCS, INC. STREET 2: 1405 RESEARCH BLVD., STE. 125 CITY: ROCKVILLE STATE: MD ZIP: 20850 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Sensei Biotherapeutics, Inc. CENTRAL INDEX KEY: 0001829802 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1405 RESEARCH BLVD, SUITE 125 CITY: ROCKVILLE STATE: MD ZIP: 20850 BUSINESS PHONE: (240) 243-8000 MAIL ADDRESS: STREET 1: 1405 RESEARCH BLVD, SUITE 125 CITY: ROCKVILLE STATE: MD ZIP: 20850 4 1 form4-02162024_110205.xml X0508 4 2024-02-15 0001829802 Sensei Biotherapeutics, Inc. SNSE 0001843563 Colgan Erin C/O SENSEI BIOTHERAPEUTICS, INC. 1405 RESEARCH BLVD, SUITE 125 ROCKVILLE MD 20850 false true false false CHIEF FINANCIAL OFFICER 0 Common Stock 2024-02-15 4 F 0 3627 0.79 D 67462 D Stock Option (Right to Buy) 0.79 2024-02-15 4 A 0 125000 0 A 2034-02-14 Common Stock 125000 125000 D Stock Option (Right to Buy) 0.79 2024-02-15 4 A 0 94128 0 A 2034-02-14 Common Stock 94128 94128 D Represents shares withheld to satisfy withholding tax obligations upon the vesting of restricted stock units. Includes 3,000 shares purchased by the Reporting Person on May 16, 2023 pursuant to the Issuer's 2021 Employee Stock Purchase Plan. The option shall vest over a period of four years as follows: 25% of the total number of shares subject to the option shall vest on February 15, 2025, and the remainder will vest 1/48th of total number of shares subject to the option monthly thereafter over the remaining three years, subject to the Reporting Person's continuous service with the Issuer as of each such date. Represents one-third of the Reporting Person's 2023 annual bonus, which the Compensation Committee of the Issuer determined to pay in the form of a stock option in lieu of cash. 100% of the shares are fully vested as of the date of grant. /s/ Mark Ballantyne, Attorney-in-Fact 2024-02-16